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Transplantation of cryopreserved ovarian tissue
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The lifesaving treatment endured by cancer survi-
vors provokes, in many cases, early menopause and
subsequent infertility. In clinical situations where
there is often a pressing need to start chemotherapy,
ovarian tissue cryopreservation looks to be a promi-
sing option to restore fertility.
It has been estimated that, by 2010, one in 250
people in the adult population will actually be
childhood cancer survivors (1).
The treatment of childhood malignancy is beco-
ming increasingly effective. Aggressive chemotherapy
and radiotherapy, as well as bone marrow transplanta-
tion, can cure more than 90 percent of girls and
young women affected by such malignancies.
However, the ovaries are very sensitive to cytotoxic
treatment, especially to alkylating agents and ionizing
radiation, generally resulting in the loss of both endo-
crine and reproductive function (2). Moreover, it is
known that uterine irradiation at a young age reduces
adult uterine volume (3).
There are several potential options available to
preserve fertility in patients facing premature ovarian
failure, including immature and mature oocyte cryo-
preservation, embryo cryopreservation and cryopre-
servation of ovarian tissue(4, 5). 
For those patients who require immediate che-
motherapy, cryopreservation of ovarian tissue is a
possible alternative (4, 6, 7). 
Hystory of experimental 
and clinical studies
To date, ovarian tissue has been successfully cryo-
preserved and transplanted in mice and rodents, as
well as large animals like sheep and marmoset
monkeys (8-10). The first successful fertilization and
pregnancy following egg collection from fresh tran-
splanted ovarian tissue in a primate was recently
described (11). The grafted tissue functioned without
any surgical connection to major blood vessels.
Experimental studies have indicated that the decrease
in the number of primordial follicles in grafted tissue
is due to hypoxia and the delay before reimplanted
cortical tissue becomes revascularized. The loss of
primordial follicles in cryopreserved ovarian tissue
after transplantation is estimated to be 50 to 65 per-
cent in some experimental studies (7,8,12). In one
experimental study, in which ovarian cortex was graf-
ted onto the uterine horn and under the skin, the loss
was found to be more than 90 percent (13).
Oktay et al have reported laparoscopic transplan-
tation of frozen-thawed ovarian tissue to the pelvic
side wall (14), to the forearm (15) and, more recently,
beneath the skin of the abdomen. A four-cell embryo
was obtained from 20 oocytes retrieved from tissue
transplanted to the latter site, but no pregnancy
occurred after transfer (16). Radford et al. reported
on a patient with a history of Hodgkin’s disease trea-
ted by chemotherapy, in whom ovarian tissue had
been biopsied and cryopreserved four years after che-
motherapy and later reimplanted (17). In this case,
histological section of ovarian cortical tissue revealed
only a few primordial follicles because of the previous
chemotherapy. After reimplantation, the patient had
only one menstrual period. 
Very recently, the first livebirth after a fresh ova-
rian tissue transplant in a primate was reported (11).
We have described a livebirth after orthotopic
autotransplantation of cryopreserved ovarian tissue.
Our findings suggest that cryopreservation of ovarian
tissue should be offered to all young women diagno-
sed with cancer (18).
Freeze-thawing
Freezing of ovarian tissue was carried out accor-
ding to the protocol described by Gosden et al [6].
The biopsies were immediately transferred to the
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laboratory in Leibovitz L-15 medium supplemented
with Glutamax (GIBCO, Paisley, Scotland). There,
the remaining stromal tissue was gently removed.
Four biopsies of the cortex were then cut into 70
small cubes of 2x2mm. One strip of 12x4mm was left
whole.
Fragments (cubes and a strip) of ovarian tissue
were suspended in the cryoprotective medium. All
the fragments were placed into precooled 2ml cryoge-
nic vials (Simport, Quebec, Canada) filled with
Leibovitz medium supplemented with 4mg/ml of
human serum albumin (Red Cross, Brussels, Belgium)
and 1.5mM DMSO (Sigma, St. Louis, MO).  The
cryotubes were cooled in a programmable freezer
(Kryo 10, Series III; Planer, Sunbury-on-Thames,
United Kingdom) using the following program: (1)
cooled from 0°C to –8°C at –2°C/min; (2) seeded
manually by touching the cryotubes with forceps pre-
chilled in liquid nitrogen; (3) cooled to – 40°C at –
0.3°C/min; (4) cooled to –150°C at –30°C/min, and
(5) transferred to liquid nitrogen (-196°C) immedia-
tely for storage.
Reimplantation of ovarian 
cortical tissue
In 1997, a 25-year-old woman presented with cli-
nical stage IV Hodgkin’s lymphoma. Ovarian tissue
cryopreservation was carried out before chemothe-
rapy. Written informed consent was obtained. Using
laparoscopy, 5 biopsies, about 1.2-1.5cm long and
5mm wide, were taken from the left ovary. Removing
the whole ovary was not an option, as one can never
completely exclude recovery of ovarian function after
chemotherapy. Indeed, premature ovarian failure after
chemotherapy is age-, drug- and dose-dependent and
does not occur in 100% of cases. 
After laparoscopy, the patient received
MOPP/ABV hybrid chemotherapy (mechlorethami-
ne, vincristine, procarbazine, prednisone, adriamycin,
bleomycin, vinblastine) from August 1997 to
February 1998, followed by radiotherapy (38 grays).
She became amenorrheic shortly after the initia-
tion of chemotherapy. The levels of follicle-stimula-
ting hormone (FSH), luteinizing hormone (LH) and
estradiol (E2) following chemo- and radiotherapy
were, respectively, 91.1 mIU/ml, 85 mIU/ml and 17
pg/ml, confirming castration. This ovarian failure
profile was confirmed three months later. Hormone
replacement therapy (HRT) was started in June 1998
and then stopped in January 2001, as the patient
wished to become pregnant. A thorough evaluation
by oncologists demonstrated that she was disease-
free.
After cessation of HRT, FSH, LH and 17 b-estra-
diol levels returned to levels consistent with ovarian
failure.  From January 2001 to December 2002, the
patient experienced only one ovulatory cycle? proved
by a progesterone level of 10 nmg/ml and the pre-
sence of a corpus luteum on the left ovary, diagnosed
by vaginal echography. The decision to reimplant was
therefore taken. 
A first laparoscopy was carried out 7 days before
reimplantation in order to create a peritoneal window
by means of a large incision just beneath the right
ovarian hilus, followed by coagulation of the edges of
the window. The goal was to induce angiogenesis and
neovascularization in this area. Both ovaries looked
atrophic. Nevertheless, a small corpus luteum was
visible on the left ovary. A decrease in LH and FSH
was observed and the concentrations then returned
to castrated levels. A second laparoscopy was carried
out seven days after the creation of the peritoneal
window. A biopsy of 4-5mm in size was taken from
each of the atrophic ovaries in order to check for the
presence or absence of primordial follicles.
The thawed ovarian cortical tissue was then placed
in sterile medium and immediately transferred to the
operating theatre. The large strip and 35 small cubes
of frozen-thawed ovarian tissue were pushed into the
furrow created by the peritoneal window very close
to the ovarian vessels and fimbria on the right side.
No suture was used. An extensive neovascular
network was clearly visible in this space 
A third laparoscopy was carried out four and a
half months after reimplantation to evaluate the sur-
vival of the graft. A follicle was visible at the site of
reimplantation. Biopsy was performed. 
The grafted tissue was biopsied and histology and
fluorescent probe staining revealed the presence of
viable primordial follicles and a follicular structure
with inhibin A-marked cells. Follicles at an early
growth stage require more than 85 days to reach the
antral stage (19). Primordial follicles obviously require
even more. The appearance of the first follicle in the
grafted tissue five months after reimplantation is
totally consistent with the expected time course. This
time interval observed in our study between implan-
tation of cortical tissue and the first estradiol peak (5
months) is also consistent with data obtained from
sheep and human beings (8, 17).
From five to nine months after reimplantation,
ultrasonography revealed the development of a folli-
cle followed by corpus luteum formation with each
cycle, at the site of reimplantation. This corresponded
to an estradiol level of more than 100 pg/ml and a
progesterone level ranging from 12 to 37 ng/ml. The
LH and FSH levels were significantly (p<0.05) lower
than those observed before reimplantation. This led
to the restoration of consecutive menstrual bleeding
each month.
At nine and a half months, FSH levels increased
to 78.7 mIU/ml and returned to normal values seven
days later. Three weeks later, a follicle of 2.6cm in
size had developed on the right side, clearly outside
the right ovary. Both native ovaries were well visuali-
zed and found to be obviously atrophic. Eighteen
days after ovulation, calculated by basal body tempe-
rature, the hCG level was 2,853 mIU/ml. 
We cannot explain this sudden and temporary
surge in FSH. It is possible that it was associated with
a decline in inhibin secretion, as suggested in the
sheep model (20,21) or with slower follicular growth
from a poor follicular reserve in the graft. Indeed,
due to the loss of primordial follicles in the tran-
splant, the follicular density per mm3 was low but, in
any case, the total amount of cortical tissue transplan-
ted is relatively unimportant. After transplantation,
the patient would have been considered a poor
responder as, of the 500 to 1000 primordial follicles
that would have been transplanted, more than 50 per-
cent would have been lost due to hypoxia (12).
Is it risky?
Unfortunately, in the majority of cases, aggressive
chemotherapy and radiotherapy lead to ovarian failu-
re. The restoration of ovarian function after che-
motherapy or radiotherapy has two main goals: to
improve quality of life and restore reproductive func-
tion. For those patients who require immediate che-
motherapy, ovarian tissue cryopreservation, perfor-
med before cancer treatment is begun, may be a
means of preserving fertility without delaying the ini-
tiation of chemotherapy. However, one major con-
cern surrounding the use of ovarian cortical strips for
orthotopic autotransplantation is the potential risk
that the frozen-thawed ovarian cortex might harbour
malignant cells which could induce a recurrence of
the disease after reimplantation. Shaw et al reported
that ovarian grafts from AKR mice could transfer
lymphoma to recipient animals (22). Nevertheless,
more recent studies have suggested that ovarian tissue
transplantation in Hodgkin’s disease is safe (23-25). 
In our study, histological evaluation of ovarian
cortex before and after reimplantation demonstrated
the absence of disease. But confirming the absence of
malignant cells by light microscopy may not be suffi-
cient, especially in other types of cancer (especially
hematogenous or systemic neoplasms)(9). Screening
methods to detect minimal residual disease must be
developed to eliminate the risk of cancer cell tran-
smission with reimplantation (5).
Lines of evidence
1. The patient experienced, in total, 3 ovulatory
cycles over a period of more than two years. All of
them originated from the left native ovary. This
was proved by laparoscopy and/or echography.
2. The native right ovary never demonstrated any
ovarian activity at all (no follicles, no corpus
luteum).
3. Even if we cannot absolutely exclude the presence
of isolated follicles in the atrophic ovary, their
density must be very low since serial sections of 4
large biopsies of atrophic ovaries failed to detect
any.
4. Laparoscopy proved, by direct visualization, the
development of a follicle from the grafted tissue
five months after reimplantation.
5. Biopsy proved, by histologic examination, not
only the survival of primordial follicles in the graf-
ted tissue, but also the maturation of a follicle
(granula-cells marked by inhibin-A). This is the
first time that survival of primordial follicles has
been histologically proved after cryopreserved
ovarian tissue transplantation.
6. After follicular development was proved by lapa-
roscopy and histology, the patient experienced
regular menstrual bleeding. The progesterone level
was systematically more than 10ng/ml in the mid-
luteal phase, calculated on the basis of BBT.
During each ovulatory cycle (from 5 to 9 months),
vaginal echography demonstrated a corpus luteum
on the grafted tissue outside the right atrophic
ovary, which had demonstrated no ovarian activity
for almost 3 years.
7. Finally, vaginal echography revealed the presence
of a preovulatory follicle at the reimplantation site
during the cycle leading to the pregnancy, but no
follicles were seen on either of the native ovaries.
This argument is a crucial one.
Conclusion
This is the first report of the birth of a healthy
infant, obtained after orthotopic autotransplantation
of cryopreserved ovarian tissue. It opens new per-
spectives for young cancer patients facing premature
ovarian failure. Ovarian tissue cryopreservation
should be an option offered to all young women dia-
gnosed with cancer, in conjunction with other exi-
sting options for fertility preservation such as imma-
ture oocyte retrieval, in vitro maturation of oocytes,
oocyte vitrification or embryo cryopreservation. 
Even if more and more papers are now describing
the restoration of ovarian function after orthotopic
transplantation of fresh and frozen ovarian tissue and
the first livebirth has recently been reported, we
should still bear in mind that many questions remain
unanswered. In our department, research is presently
under way on freezing an entire ovary. A recent paper
by our group described not only the technique, but
also the high rate of survival of primordial follicles
after freeze-thawing an entire ovary [26,27]. This
could lead to the transplantation of an intact ovary,
with microvascular anastomosis carried out to restore
immediate vascularization and minimize post-tran-
splantation ischemia responsible for the reduction in
follicular density.
A major limitation of intact organ transplantation,
which needs to be investigated, is the problem of sto-
rage of an intact ovary with its vascular tissue. 
Other issues, like the question of the optimum
number of grafts and hence oocytes, how long the
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